Vanguard Global Advisers
LPCN icon

Vanguard Global Advisers’s Lipocine LPCN Stock Holding History

Vanguard Global Advisers’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.72K Hold
1,691
– – ﹤0.01% 3620
2026
Q2 		$4.33K Hold
1,691
– – ﹤0.01% 3563
2026
Q1 		$13.5K Buy
+1,691
New +$14.7K ﹤0.01% 3428

Other funds holding LPCN

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Birchview Capital
Birchview Capital Burlington, Vermont $173M AUM 89.27% 1-Year Est. Return

Vanguard Global Advisers's LPCN Position: Q3 2026 in Review

Vanguard Global Advisers held its Lipocine (LPCN) position steady in Q3 2026 at 1,691 shares worth $3.72K. The position accounts for ﹤0.01% of the portfolio, ranked #3620.

Vanguard Global Advisers first reported a position in LPCN in Q1 2026 and has held it in 3 quarters since. The position peaked at $13.5K in Q1 2026. 24 funds tracked by Wall St. Rank hold LPCN as of Q3 2026.

  • Vanguard Global Advisers held 1,691 shares of Lipocine worth $3.72K as of Q3 2026.
  • Vanguard Global Advisers left its Lipocine share count unchanged in Q3 2026.
  • Lipocine made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3620 holding.
  • Vanguard Global Advisers first reported a position in Lipocine in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Lipocine position peaked at $13.5K in Q1 2026.
  • 24 funds tracked by Wall St. Rank held Lipocine as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.